215 related articles for article (PubMed ID: 33564917)
1. Effects of iguratimod on glucocorticoid-induced disorder of bone metabolism in vitro.
Miyama A; Ebina K; Hirao M; Okamura G; Etani Y; Takami K; Goshima A; Miura T; Oyama S; Kanamoto T; Yoshikawa H; Nakata K
J Bone Miner Metab; 2021 Jul; 39(4):639-648. PubMed ID: 33564917
[TBL] [Abstract][Full Text] [Related]
2. Iguratimod suppresses sclerostin and receptor activator of NF-κB ligand production via the extracellular signal-regulated kinase/early growth response protein 1/tumor necrosis factor alpha pathway in osteocytes and ameliorates disuse osteoporosis in mice.
Miura T; Etani Y; Noguchi T; Hirao M; Takami K; Goshima A; Kurihara T; Fukuda Y; Ochiai N; Kanamoto T; Nakata K; Okada S; Ebina K
Bone; 2024 Apr; 181():117026. PubMed ID: 38325651
[TBL] [Abstract][Full Text] [Related]
3. Iguratimod inhibits osteoclastogenesis by modulating the RANKL and TNF-α signaling pathways.
Li CH; Ma ZZ; Jian LL; Wang XY; Sun L; Liu XY; Yao ZQ; Zhao JX
Int Immunopharmacol; 2021 Jan; 90():107219. PubMed ID: 33307512
[TBL] [Abstract][Full Text] [Related]
4. Melatonin rescues glucocorticoid-induced inhibition of osteoblast differentiation in MC3T3-E1 cells via the PI3K/AKT and BMP/Smad signalling pathways.
Zhao R; Tao L; Qiu S; Shen L; Tian Y; Gong Z; Tao ZB; Zhu Y
Life Sci; 2020 Sep; 257():118044. PubMed ID: 32622944
[TBL] [Abstract][Full Text] [Related]
5. Iguratimod (T-614) suppresses RANKL-induced osteoclast differentiation and migration in RAW264.7 cells via NF-κB and MAPK pathways.
Gan K; Yang L; Xu L; Feng X; Zhang Q; Wang F; Tan W; Zhang M
Int Immunopharmacol; 2016 Jun; 35():294-300. PubMed ID: 27085680
[TBL] [Abstract][Full Text] [Related]
6. Bone morphogenetic protein-2 restores mineralization in glucocorticoid-inhibited MC3T3-E1 osteoblast cultures.
Luppen CA; Smith E; Spevak L; Boskey AL; Frenkel B
J Bone Miner Res; 2003 Jul; 18(7):1186-97. PubMed ID: 12854828
[TBL] [Abstract][Full Text] [Related]
7. Osteoblastogenesis and osteoprotection enhanced by flavonolignan silibinin in osteoblasts and osteoclasts.
Kim JL; Kang SW; Kang MK; Gong JH; Lee ES; Han SJ; Kang YH
J Cell Biochem; 2012 Jan; 113(1):247-59. PubMed ID: 21898547
[TBL] [Abstract][Full Text] [Related]
8. Effects of JSOG-6 on protection against bone loss in ovariectomized mice through regulation of osteoblast differentiation and osteoclast formation.
Chung HJ; Cho L; Shin JS; Lee J; Ha IH; Park HJ; Lee SK
BMC Complement Altern Med; 2014 Jun; 14():184. PubMed ID: 24903150
[TBL] [Abstract][Full Text] [Related]
9. Inhibition of heat shock protein 90 rescues glucocorticoid-induced bone loss through enhancing bone formation.
Chen H; Xing J; Hu X; Chen L; Lv H; Xu C; Hong D; Wu X
J Steroid Biochem Mol Biol; 2017 Jul; 171():236-246. PubMed ID: 28408351
[TBL] [Abstract][Full Text] [Related]
10. Poligoni Multiflori Radix enhances osteoblast formation and reduces osteoclast differentiation.
Han SY; Lee KH; Kim YK
Int J Mol Med; 2018 Jul; 42(1):331-345. PubMed ID: 29620250
[TBL] [Abstract][Full Text] [Related]
11. Aging increases stromal/osteoblastic cell-induced osteoclastogenesis and alters the osteoclast precursor pool in the mouse.
Cao JJ; Wronski TJ; Iwaniec U; Phleger L; Kurimoto P; Boudignon B; Halloran BP
J Bone Miner Res; 2005 Sep; 20(9):1659-68. PubMed ID: 16059637
[TBL] [Abstract][Full Text] [Related]
12. Inhibition of osteoclast differentiation and collagen antibody-induced arthritis by CTHRC1.
Jin YR; Stohn JP; Wang Q; Nagano K; Baron R; Bouxsein ML; Rosen CJ; Adarichev VA; Lindner V
Bone; 2017 Apr; 97():153-167. PubMed ID: 28115279
[TBL] [Abstract][Full Text] [Related]
13. The dual-effects of LaCl₃ on the proliferation, osteogenic differentiation, and mineralization of MC3T3-E1 cells.
Liu D; Zhang J; Wang G; Liu X; Wang S; Yang M
Biol Trace Elem Res; 2012 Dec; 150(1-3):433-40. PubMed ID: 22886987
[TBL] [Abstract][Full Text] [Related]
14. Arecoline suppresses RANKL-induced osteoclast differentiation in vitro and attenuates LPS-induced bone loss in vivo.
Liu FL; Chen CL; Lai CC; Lee CC; Chang DM
Phytomedicine; 2020 Apr; 69():153195. PubMed ID: 32200293
[TBL] [Abstract][Full Text] [Related]
15. Substance P stimulates bone marrow stromal cell osteogenic activity, osteoclast differentiation, and resorption activity in vitro.
Wang L; Zhao R; Shi X; Wei T; Halloran BP; Clark DJ; Jacobs CR; Kingery WS
Bone; 2009 Aug; 45(2):309-20. PubMed ID: 19379851
[TBL] [Abstract][Full Text] [Related]
16. Activation of dimeric glucocorticoid receptors in osteoclast progenitors potentiates RANKL induced mature osteoclast bone resorbing activity.
Conaway HH; Henning P; Lie A; Tuckermann J; Lerner UH
Bone; 2016 Dec; 93():43-54. PubMed ID: 27596806
[TBL] [Abstract][Full Text] [Related]
17. MicroRNA-17/20a inhibits glucocorticoid-induced osteoclast differentiation and function through targeting RANKL expression in osteoblast cells.
Shi C; Qi J; Huang P; Jiang M; Zhou Q; Zhou H; Kang H; Qian N; Yang Q; Guo L; Deng L
Bone; 2014 Nov; 68():67-75. PubMed ID: 25138550
[TBL] [Abstract][Full Text] [Related]
18. Water extract of Rumex crispus prevents bone loss by inhibiting osteoclastogenesis and inducing osteoblast mineralization.
Shim KS; Lee B; Ma JY
BMC Complement Altern Med; 2017 Oct; 17(1):483. PubMed ID: 29070038
[TBL] [Abstract][Full Text] [Related]
19. Trapidil, a platelet-derived growth factor antagonist, inhibits osteoclastogenesis by down-regulating NFATc1 and suppresses bone loss in mice.
Kim SD; Kim HN; Lee JH; Jin WJ; Hwang SJ; Kim HH; Ha H; Lee ZH
Biochem Pharmacol; 2013 Sep; 86(6):782-90. PubMed ID: 23928189
[TBL] [Abstract][Full Text] [Related]
20. Shikimic Acid Inhibits Osteoclastogenesis in Vivo and in Vitro by Blocking RANK/TRAF6 Association and Suppressing NF-κB and MAPK Signaling Pathways.
Chen X; Li X; Zhai X; Zhi X; Cao L; Qin L; Su J
Cell Physiol Biochem; 2018; 51(6):2858-2871. PubMed ID: 30562759
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
